Kanada - İngilizce - Health Canada

sanofi pasteur limited - recombinant haemagglutinin protein-strain a (h1n1); recombinant haemagglutinin protein-strain a (h3n2); recombinant haemagglutinin protein-strain b (victoria); recombinant haemagglutinin protein-strain b (yamagata) - solution - 45mcg; 45mcg; 45mcg; 45mcg - recombinant haemagglutinin protein-strain a (h1n1) 45mcg; recombinant haemagglutinin protein-strain a (h3n2) 45mcg; recombinant haemagglutinin protein-strain b (victoria) 45mcg; recombinant haemagglutinin protein-strain b (yamagata) 45mcg - vaccines

ABD - İngilizce - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen (unii: 1iqz1wce3y) (influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen - unii:1iqz1wce3y), influenza b virus b/massachusetts/2/2012 recombinant hemagglutinin antigen (unii: ayr0wzx7jh) (influenza b virus b/massachus - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 through 49 years of age. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis), to any component of the vaccine (see description [11]).  reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to flublok. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this vaccine should be used during pregnancy only if clearly needed. the effect of flublok on embryo-fetal and pre-weaning development was evaluated in pregnant rats. animals were administered flublok by intramuscular injection twice prior to gestation and once during the period of organ

ABD - İngilizce - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen (unii: 1iqz1wce3y) (influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen - unii:1iqz1wce3y), influenza b virus b/massachusetts/2/2012 recombinant hemagglutinin antigen (unii: ayr0wzx7jh) (influenza b virus b/massachus - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 years of age and older. in persons 18 through 49 years of age, this indication is based on a controlled clinical study demonstrating a decrease in influenza disease after vaccination with flublok. in persons 50 years of age and older, this indication is based on the immune response elicited by flublok; data demonstrating a decrease in influenza disease in persons 50 years and older after vaccination with flublok are not available. (see clinical studies [ 14]) flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see description [11] and postmarketing experience [6.2]). reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to

ABD - İngilizce - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/switzerland/9715293/2013 (h3n2) recombinant hemagglutinin antigen (unii: d2053d6yqu) (influenza a virus a/switzerland/9715293/2013 (h3n2) recombinant hemagglutinin antigen - unii:d2053d6yqu), influenza b virus b/phuket/3073/2013 recombinant hemagglutinin antigen (unii: poq8dqo9s3) (influenza b - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 years of age and older. in persons 18 through 49 years of age, this indication is based on a controlled clinical study demonstrating a decrease in influenza disease after vaccination with flublok. in persons 50 years of age and older, this indication is based on the immune response elicited by flublok; data demonstrating a decrease in influenza disease in persons 50 years and older after vaccination with flublok are not available. (see clinical studies [ 14] ) flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see description [11] and postmarketing experience [6.2] ). reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm t

ABD - İngilizce - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen (unii: 2i1eol437m) (influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen - unii:2i1eol437m), influenza b virus b/brisbane/60/2008 recombinant hemagglutinin antigen (unii: 058u2312cr) (influenza b virus b/b - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 years of age and older. in persons 18 through 49 years of age, this indication is based on a controlled clinical study demonstrating a decrease in influenza disease after vaccination with flublok. in persons 50 years of age and older, this indication is based on the immune response elicited by flublok; data demonstrating a decrease in influenza disease in persons 50 years and older after vaccination with flublok are not available. (see clinical studies [ 14] ) flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see description [11] and postmarketing experience [6.2] ). reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm t

ABD - İngilizce - NLM (National Library of Medicine)

novartis vaccines and diagnostics limited - influenza a virus a/california/7/2009 x-181 (h1n1) antigen (formaldehyde inactivated) (unii: 872508x6jg) (influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:5cl7878s2q) - influenza a virus a/california/7/2009 x-181 (h1n1) antigen (formaldehyde inactivated) 15 ug in 0.5 ml

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1v) 2009 virus.focetria should be used in accordance with official guidance.

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus inactivated, containing antigen equivalent to a/california/07/2009 (h1n1)-derived strain used nymc x-179a - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1)v 2009 virus. pandemrix should only be used if the recommended annual seasonal trivalent / quadrivalent influenza vaccines are not available and if immunisation against (h1n1)v is considered necessary (see sections 4.4 and 4.8).pandemrix should be used in accordance with official guidance.

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

lupin healthcare (uk) ltd - lisinopril - oral tablet - 2.5mg

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - influenza vaccine whole virion, vero cell derived, inactivated 7.5ug (a(h5n1) (a/vietnam/1203/2004));   - suspension for injection - 7.5 mcg/0.5ml - active: influenza vaccine whole virion, vero cell derived, inactivated 7.5ug (a(h5n1) (a/vietnam/1203/2004))   excipient: polysorbate 80 sodium chloride trometamol water for injection - prophylaxis of influenza in an officially declared pandemic situation. the vaccine may only be marketed or distributed in accordance with the directives contained in the current version of the new zealand influenza pandemic action plan.